enGene Therapeutics
ENGN
31 hedge funds and large institutions have $183M invested in enGene Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0.71% less ownership
Funds ownership: 81.02% → 80.31% (-0.71%)
9% less funds holding
Funds holding: 34 → 31 (-3)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
33% less capital invested
Capital invested by funds: $275M → $183M (-$91.3M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$12.5M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$742K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$260K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$148K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$14M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.54M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$417K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$196K |
| 5 |
O
OrbiMed
New York
|
-$178K |
ENGN Hedge Fund Activity: Q1 2025 in Review
31 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q1 2025, worth a combined $183M — down 33% from $275M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ENGN and 2 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Bank of America, opening a new position worth an estimated $12.5M. The largest seller was BVF Inc, exiting entirely with an estimated $14M sold.
- 31 institutional investors held enGene Therapeutics (ENGN) as of Q1 2025, down from 34 in Q4 2024.
- Funds reported $183M of enGene Therapeutics stock for Q1 2025, down 33% quarter-over-quarter.
- 2 funds opened new enGene Therapeutics positions in Q1 2025 and 5 closed out, a net change of -3 holders.
- The largest enGene Therapeutics buyer in Q1 2025 was Bank of America, an estimated $12.5M added.
- The largest enGene Therapeutics seller in Q1 2025 was BVF Inc, an estimated $14M sold.
Based on aggregated 13F filings for Q1 2025.